Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Catherine Becht
Clinique de Clémentville
Montpelier
France
Contact
Clinique de Clémentville
Email
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
186
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Weekly Paclitaxel Plus Bevacizumab versus Docetaxel As Second- or Third-Line Treatment in Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Results of the IFCT-1103 ULTIMATE Study
Number of pages: 37
Posted: 29 Jun 2019
Alexis Cortot
,
Clarisse Audigier-Valette
,
Olivier Molinier
,
Sylvestre Le Moulec
,
Fabrice Barlesi
,
Gerard Zalcman
,
Patrick Dumont
,
Damien Pouessel
,
Claire Poulet
,
Sandrine Hiret
,
Adrien Dixmier
,
Patrick-Aldo Renault
, Catherine Becht,
Olivier Raffy
,
Charles Dayen
,
Julien Mazieres
,
Eric Pichon
,
Alexandra Langlais
,
Franck Morin
,
Denis Moro-Sibilot
and
Benjamin Besse
Université de Lille - Thoracic Oncology Department, CHITS Sainte Musse, Centre Hospitalier Général - Le Mans, Bergonié Institute, Aix Marseille Université, Hopital Bichat Claude Bernard, Centre Hospitalier - Chauny, University of Paris - Saint Louis Hospital, Centre Hospitalier Universitaire Lyon Sud, Institut de Cancérologie de l'Ouest, Centre Hospitalier Régional Orleans, Centre Hospitalier - Pau, Clinique de Clémentville, Centre Hospitalier Louis Pasteur, Centre Hospitalier - Saint Quentin, Hôpital Larrey, François Rabelais University - CHU Bretonneau - CHU Hôpitaux De Tours, Intergroupe Francophone de Cancérologie Thoracique, Intergroupe Francophone de Cancérologie Thoracique, CHU Grenoble-Alpes and Comité de Pathologies Thoraciques
Downloads
186
(407,391)
View PDF
Download
Abstract:
NSCLC, paclitaxel, docetaxel, bevacizumab
Feedback